查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1782997

全球胜肽和寡核苷酸CDMO市場

Peptide and Oligonucleotide CDMO
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 370 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球胜肽和寡核苷酸 CDMO 市場規模將達到 57 億美元

全球胜肽和寡核苷酸CDMO市場規模預計在2024年為28億美元，預計到2030年將達到57億美元，在2024-2030年的分析期內，複合年成長率為12.8%。肽類是本報告分析的細分市場之一，預計其複合年成長率為14.1%，到分析期結束時規模將達到42億美元。寡核苷酸細分市場在分析期間內的複合年成長率估計為9.4%。

美國市場規模估計為 7.523 億美元，中國市場預計複合年成長率為 17.3%

美國胜肽和寡核苷酸CDMO市場規模預計在2024年達到7.523億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到12億美元，在2024-2030年的分析期內，複合年成長率將達到17.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為9.2%和11.4%。在歐洲，預計德國市場的複合年成長率將達到10.1%。

全球胜肽和寡核苷酸 CDMO 市場 - 主要趨勢和促進因素摘要

什麼是胜肽和寡核苷酸 CDMO？

胜肽和寡核苷酸合約開發與受託製造廠商(CDMO) 專門從事胜肽和寡核苷酸的開發和生產。這些生物製藥對於開發多種疾病的治療方法至關重要，包括癌症、自體免疫疾病、遺傳性疾病和病毒感染疾病。胜肽和寡核苷酸 CDMO 的作用是提供與這些複雜分子的研究、開發和大規模生產相關的服務。這些服務通常包括藥物發現、製程開發、製造和商業化支持，確保產品符合製藥業的嚴格監管要求。

與傳統小分子藥物相比，肽類藥物因其特異性更高、毒性更低而日益受到青睞。寡核苷酸（包括基於RNA的療法和反義寡核苷酸等產品）因其靶向和調控基因表現的能力而變得越來越重要。專注於胜肽類和寡核苷酸的CDMO（合約開發生產組織）幫助製藥公司克服生產這些高度專業化分子的挑戰，包括克服與可擴展性、純度、產量最佳化以及確保合規性相關的挑戰。隨著胜肽類和寡核苷酸藥物市場的持續擴張，預計該領域對CDMO服務的需求將大幅成長。

胜肽和寡核苷酸 CDMO 市場為何不斷擴大？

胜肽和寡核苷酸CDMO市場正在擴張，這得益於幾個關鍵因素，包括生技藥品和個人化醫療的興起、RNA療法的進步以及慢性病盛行率的上升。其中一個最顯著的促進因素是生物製藥（尤其是胜肽和生物製藥）的日益普及，它們特異性高、副作用少，能夠治療先前難以控制的疾病，例如罕見遺傳疾病、某些癌症和病毒感染疾病。

RNA治療方法的進步也是推動胜肽和寡核苷酸 CDMO 市場成長的重要因素。 mRNA 疫苗在對抗 COVID-19 疫情的成功，凸顯了 RNA 技術在醫療保健領域的潛力。因此，對寡核苷酸製造服務的需求正在快速成長，尤其是對 mRNA 疫苗、基因編輯工具和RNA干擾療法等產品的需求。製藥和生物技術公司擴大尋求在此類複雜分子製造和開發方面擁有專業知識的 CDMO 合作夥伴。隨著 RNA 療法研究的深入，對包括小干擾 RNA (siRNA)、傳訊RNA(mRNA) 和反義寡核苷酸 (ASO) 在內的寡核苷酸的需求預計將持續上升。

此外，癌症、糖尿病和心血管疾病等慢性疾病的日益流行，也推動了對新型治療方法的需求，包括胜肽和寡核苷酸。隨著世界人口老化，對在分子層面上針對這些疾病根本病因的創新藥物的需求日益成長。這導致越來越多的基於胜肽和寡核苷酸的候選藥物進入臨床和商業化階段，進一步增加了對CDMO提供的專業生產和開發服務的需求。

影響胜肽和寡核苷酸 CDMO 未來的主要趨勢是什麼？

胜肽和寡核苷酸CDMO市場的未來正受到多種變革趨勢的影響，包括製造技術的進步、品質和法規遵循日益重要，以及對擴充性和靈活性的日益關注。其中一個關鍵趨勢是胜肽和寡核苷酸合成技術的進步，這使得製造流程更快、更有效率、更具成本效益。固相胜肽合成(SPPS)、連續流化學和自動化高通量系統等創新技術正在提高大規模生產高品質胜肽和寡核苷酸的能力，這對於滿足日益成長的全球需求至關重要。

此外，包括胜肽和寡核苷酸在內的生技藥品的法規環境日益嚴格，這進一步要求CDMO加強品管措施，確保符合全球法規。這包括滿足美國FDA和歐洲藥品管理局(EMA)等監管機構制定的要求，這些機構對生技藥品的開發、生產和分銷制定了嚴格的指導方針。隨著生技藥品日益複雜，CDMO必須始終領先於不斷發展的監管標準，並採用最佳實踐，以確保其生產流程完全合規，並生產出純度和功效達到最高水平的治療藥物。

另一個關鍵趨勢是對靈活且可擴展的生產解決方案的需求日益成長。隨著基於胜肽和寡核苷酸的療法在臨床研發管線中不斷推進，藥物開發商需要能夠提供靈活生產能力的CDMO，並能夠隨著藥物開發的進展而擴展。這種靈活性對於製藥公司在保持成本效益、品質和法規合規性的同時高效擴大生產規模至關重要。隨著個人化醫療和標靶治療的日益普及，CDMO也需要具備適應能力，以提供能夠滿足每種候選藥物獨特需求的客製化解決方案。

推動胜肽和寡核苷酸 CDMO 市場成長的因素有哪些？

胜肽和寡核苷酸CDMO市場的成長受到多種因素的推動，包括對生技藥品需求的不斷成長、RNA治療方法的進步以及對基因標靶療法研究的活性化。隨著製藥業持續向生物製藥轉型，胜肽和寡核苷酸因其能夠更精準地靶向特定生物過程且副作用更少而備受關注。這導致專注於這些治療方法的研發活動激增，從而導致對能夠提供這些分子製造和規模化專業知識的專業CDMO服務的需求增加。

RNA治療方法（尤其是 mRNA 疫苗和基因療法）的快速發展和核准，進一步加速了 CDMO 產業的成長。隨著新冠疫情 mRNA 疫苗的成功研發，人們對擴大 RNA 技術的應用範圍以治療更多疾病的興趣日益濃厚。這導致對擁有先進寡核苷酸合成和 RNA 生產能力的 CDMO 的需求日益成長。隨著 RNA 療法產品線的不斷拓展，專注於寡核苷酸生產的 CDMO 具備優勢，能夠支持製藥公司擴大生產規模，以用於臨床試驗和商業性上市。

此外，個人化醫療日益受到重視，這推動了對更專業、小規模、高品質胜肽和寡核苷酸生產服務的需求。隨著越來越多的藥物被開發用於針對特定基因標記或疾病亞型，能夠適應小批量客製化並保持高品質的精準生產變得越來越重要。為了支持這些創新，對能夠提供靈活、可擴展且高品質生產能力的CDMO的需求日益成長。此外，慢性病的日益普及以及基因編輯療法的轉變，也促進了胜肽和寡核苷酸CDMO市場的擴張。

部分

產品類型（胜肽、寡核苷酸）；服務類型（契約製造服務、合約開發服務）；最終用戶（製藥公司、生物製藥公司、其他最終用戶）

受訪公司範例

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec SA
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd.（WuXi STA）
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP32516

Global Peptide and Oligonucleotide CDMO Market to Reach US$5.7 Billion by 2030

The global market for Peptide and Oligonucleotide CDMO estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Peptides, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Oligonucleotides segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$752.3 Million While China is Forecast to Grow at 17.3% CAGR

The Peptide and Oligonucleotide CDMO market in the U.S. is estimated at US$752.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Peptide and Oligonucleotide CDMO Market - Key Trends & Drivers Summarized

What Is a Peptide and Oligonucleotide CDMO and How Does It Work?

A Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) specializes in the development and manufacturing of peptides and oligonucleotides, which are short chains of amino acids and nucleotides, respectively. These biopharmaceutical products are crucial in the development of therapeutics for a range of diseases, including cancer, autoimmune disorders, genetic diseases, and viral infections. The role of a peptide and oligonucleotide CDMO is to provide services related to the research, development, and large-scale production of these complex molecules. These services typically include drug discovery, process development, manufacturing, and commercialization support, ensuring that the products meet the stringent regulatory requirements of the pharmaceutical industry.

Peptide drugs are gaining significant traction due to their specificity and lower toxicity compared to traditional small-molecule drugs. Oligonucleotides, which include products like RNA-based therapeutics and antisense oligonucleotides, are becoming increasingly important for their ability to target and modulate gene expression. CDMOs focused on peptides and oligonucleotides help pharmaceutical companies navigate the challenges of producing these highly specialized molecules. This includes overcoming challenges related to scalability, purity, yield optimization, and ensuring regulatory compliance. As the market for peptide and oligonucleotide-based drugs continues to expand, the demand for CDMO services in this space is poised to increase substantially.

Why Is the Peptide and Oligonucleotide CDMO Market Expanding?

The peptide and oligonucleotide CDMO market is growing due to several key factors, including the rise of biologics and personalized medicine, advances in RNA therapies, and the increasing prevalence of chronic diseases. One of the most prominent drivers is the growing shift toward biologic drugs, particularly peptides and oligonucleotides, which are considered more targeted and precise compared to traditional small-molecule drugs. These biologics offer higher specificity, fewer side effects, and can be used to treat diseases that were previously challenging to manage, such as rare genetic disorders, certain cancers, and viral infections.

The advancement of RNA-based therapies is another major factor contributing to the growth of the peptide and oligonucleotide CDMO market. The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of RNA technologies in medicine. As a result, the demand for oligonucleotide manufacturing services is rapidly increasing, particularly for products like mRNA vaccines, gene-editing tools, and RNA interference therapies. Pharmaceutical companies and biotech firms are increasingly seeking CDMO partners with expertise in the production and development of these complex molecules. The demand for oligonucleotides, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), is expected to continue its upward trajectory as research into RNA therapeutics expands.

In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is driving the need for novel therapeutic approaches, including those involving peptides and oligonucleotides. As the global population ages, there is an escalating demand for innovative drugs that target the underlying causes of these diseases at a molecular level. This has led to a growing number of peptide and oligonucleotide-based drug candidates entering the clinical and commercial stages, further increasing the demand for specialized manufacturing and development services offered by CDMOs.

What Key Trends Are Shaping the Future of Peptide and Oligonucleotide CDMOs?

The future of the peptide and oligonucleotide CDMO market is being shaped by several transformative trends, including advances in manufacturing technologies, the increasing importance of quality and regulatory compliance, and the growing focus on scalability and flexibility. One key trend is the advancement of peptide and oligonucleotide synthesis technologies, which are enabling faster, more efficient, and cost-effective manufacturing processes. Innovations in solid-phase peptide synthesis (SPPS), continuous-flow chemistry, and automated high-throughput systems are improving the ability to produce high-quality peptides and oligonucleotides at scale, which is critical for meeting the increasing global demand.

Additionally, the regulatory environment for biologics, including peptides and oligonucleotides, is becoming more stringent, driving the need for CDMOs to enhance their quality control measures and ensure compliance with global regulations. This includes meeting the requirements set by regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA), which have strict guidelines for the development, manufacturing, and distribution of biologics. As the complexity of biologics increases, CDMOs will need to stay ahead of evolving regulatory standards and adopt best practices to ensure that their manufacturing processes are fully compliant and capable of producing therapeutics with the highest levels of purity and efficacy.

Another important trend is the growing demand for flexible and scalable manufacturing solutions. As peptide and oligonucleotide-based therapeutics move through the clinical pipeline, drug developers require CDMOs that can provide flexible manufacturing capabilities that scale with the progression of the drug’s development. This flexibility is essential as it allows pharmaceutical companies to efficiently scale up production while maintaining cost-effectiveness, quality, and regulatory compliance. As personalized medicine and targeted therapies become more common, CDMOs will also need to be adaptable in offering customized solutions that can cater to the unique needs of individual drug candidates.

What Are the Key Drivers of Growth in the Peptide and Oligonucleotide CDMO Market?

The growth in the peptide and oligonucleotide CDMO market is driven by several factors, including increasing demand for biologics, advancements in RNA-based therapies, and growing research into gene-targeted treatments. As the pharmaceutical industry continues to shift toward biologic drugs, peptides and oligonucleotides have gained significant attention due to their ability to target specific biological processes with higher precision and fewer side effects. This has led to a surge in research and development activities focused on these therapeutic modalities, thereby increasing the demand for specialized CDMO services that can provide expertise in the manufacturing and scale-up of these molecules.

The rapid development and approval of RNA-based therapies, especially mRNA vaccines and gene therapies, have further fueled growth in the CDMO sector. Following the success of mRNA vaccines for COVID-19, there has been a heightened interest in expanding the application of RNA technologies to treat a broader range of diseases. This has driven the need for CDMOs with advanced capabilities in oligonucleotide synthesis and RNA production. As the pipeline for RNA-based therapeutics grows, CDMOs that specialize in oligonucleotide manufacturing are well-positioned to support pharmaceutical companies as they scale up production for clinical trials and commercial launch.

Additionally, the increasing focus on personalized medicine is driving the need for more specialized, small-scale, high-quality peptide and oligonucleotide manufacturing services. As more drugs are developed to target specific genetic markers or disease subtypes, there is a greater emphasis on precision manufacturing that can accommodate smaller, customized batches while maintaining high levels of quality. CDMOs that offer flexible, scalable, and high-quality production capabilities are increasingly in demand to support these innovations. Moreover, the growing prevalence of chronic diseases and the shift toward gene-editing therapies are contributing to the expansion of the peptide and oligonucleotide CDMO market, as these technologies offer new avenues for treating previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Peptide and Oligonucleotide CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Peptides, Oligonucleotides); Service Type (Contract Manufacturing Service, Contract Development Service); End-Use (Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Almac Group
  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Holding AG
  • BioSynthesis Inc.
  • Catalent, Inc.
  • CordenPharma International
  • EUROAPI
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Merck KGaA
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Senn Chemicals AG
  • STA Pharmaceutical Co., Ltd. (WuXi STA)
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide and Oligonucleotide CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Therapies Propels Growth of Peptide and Oligonucleotide CDMO Services
    • Surging Investments in mRNA and RNAi Technologies Expands Addressable Market Opportunity for Oligonucleotide CDMOs
    • Advancements in Solid-Phase Peptide Synthesis (SPPS) Strengthen Business Case for Outsourcing Complex Peptides
    • Biopharma Industry's Shift Toward Outsourcing Accelerates Demand for End-to-End CDMO Partnerships
    • Expanding Applications of Peptides in Metabolic and Oncology Therapies Drives Market Penetration
    • Regulatory Encouragement for Orphan and Rare Disease Drugs Throws the Spotlight on Oligonucleotide-Based Therapies
    • Growing Pipeline of Nucleic Acid Therapeutics Spurs Long-Term CDMO Opportunities
    • Increasing Complexity of Molecule Design Generates Demand for Specialized CDMO Capabilities
    • Personalized Medicine Trends Drive Adoption of Custom Peptide and Oligo Synthesis Services
    • Emergence of Cell and Gene Therapies Expands Synergistic Opportunities for Nucleic Acid CDMOs
    • Emergence of Next-Generation Sequencing (NGS) Tools Strengthens Market for Oligonucleotide-Enabled Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide and Oligonucleotide CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION